In diseases driven by dysfunctional microglia, could replacing them with healthy versions prevent, or even reverse, pathology? Yes, suggest two papers in the June 18 Neuron. Both describe how mice ...
Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...
The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results